Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Zevalin in Asymptomatic Follicular Lymphoma
NCT02320292Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2015
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Mayo Clinic. Primary endpoint: Complete Response Rate at 6 months. Started Feb 2015; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02320292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320292.